Amorphous Cabazitaxel Preparation via Solvent Evaporation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current forms of cabazitaxel, a potent anticancer drug, face challenges in stability and bioavailability due to its crystalline structure, which can be resistant to multidrug resistance efflux pumps and limited penetration across the blood-brain barrier, necessitating the development of a more stable and effective amorphous form.
Innovation Solution
Preparation of an amorphous form of cabazitaxel by dissolving its crystalline form in an organic solvent and removing the solvent through evaporation, vacuum condensation, or spray drying, followed by characterization using thermal analysis, X-ray diffraction, HPLC, and spectroscopy to ensure purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If crystalline form of cabazitaxel is used, then manufacturing and storage are easier, but bioavailability and stability are reduced
Solution Approach 1:
The patent changes the physical state parameter of cabazitaxel from crystalline to amorphous form. This parameter change eliminates the ordered crystal lattice structure and creates a disordered molecular arrangement, which increases bioavailability by improving dissolution rate and enhances stability by preventing crystal growth and associated degradation pathways.
Solution Approach 2:
The invention utilizes phase transition from crystalline to amorphous state. By controlling the solidification process from melt or solution, the patent achieves a metastable amorphous phase that exhibits superior pharmaceutical properties including enhanced solubility, dissolution rate, and stability compared to the stable crystalline form.
2Shape
If crystalline form of cabazitaxel is used, then structural order is maintained, but penetration across blood-brain barrier is limited
Solution Approach 1:
The patent changes the structural organization parameter from ordered crystalline arrangement to disordered amorphous arrangement. This structural parameter change reduces intermolecular interactions and increases molecular mobility, enabling better penetration across the blood-brain barrier while maintaining adequate structural integrity for stability.
3Reliability
If amorphous form is prepared by dissolving crystalline form in organic solvent and removing solvent, then bioavailability and stability are enhanced, but process complexity increases
Solution Approach 1:
The patent replaces complex mechanical crystallization control with a simpler solvent removal process. By dissolving crystalline cabazitaxel in an organic solvent and then removing the solvent through evaporation or other removal techniques, the invention achieves amorphous form conversion without requiring complex temperature-pressure control systems needed for direct crystalline-to-amorphous transitions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous form of cabazitaxel enhances bioavailability and stability, potentially overcoming multidrug resistance and improving treatment efficacy for hormone-refractory metastatic prostate cancer, while maintaining high purity and stability.
Implementation Method 1
dissolving a solid form, e.g., a crystalline form, of cabazitaxel in an organic solvent
Implementation Method 2
removing the organic solvent to dryness
Data Source
AI summary
The present invention is directed to an amorphous form of cabazitaxel, which can be prepared by dissolving a solid form of cabazitaxel in an organic solvent, and removing the organic solvent to dryness. The amorphous form of cabazitaxel is characterized by DSC as in FIG. 1 and/or X-ray powder diffraction pattern as in FIG. 2.